Skip to content

Beyond the First Draft: Scaling GenAI for End-to-End Regulatory Submissions

EMWA Spring Conference 2026, Barcelona · May 8, 2026

Watch the highlights: Beyond the First Draft: Scaling GenAI for End-to-End Regulatory Submissions
Play

At the EMWA Spring Conference 2026 in Barcelona, Matilde Thye Kveiborg, Senior Director and Head of Medical Documentation at Lundbeck, joined AlphaLife Sciences CEO Sharon Chen and AI Product Specialist Lucia D’Amado. Matilde shared the sponsor perspective: how a mid-sized pharma company is scaling GenAI in medical writing, with a particular focus on accelerating submission timelines.

From pilot to direction

Lundbeck compared a manually written clinical trial report (CTR) with CTRs prepared by its team using two AI vendor systems. Each draft was reviewed by the medical writing group and a cross-functional core reporting group, and evaluated on:

  • Output quality
  • Ease of use
  • Regulatory robustness
  • Ability to scale to other document types
  • The support model

Both pilots succeeded: each tool produced a fit-for-purpose CTR. One was significantly better, and Lundbeck chose AlphaLife Sciences. Matilde highlighted that it was simple to use, produced lean, good-quality text, and let writers prompt directly in the document to rewrite, expand or condense sections.

Moving the submission timeline forward

Before AI, Lundbeck front-loaded what it could ahead of headline results, then built up from CTRs to the clinical summaries and the clinical overview. Depending on complexity, that typically took six to nine months.

The approach Lundbeck is now exploring starts earlier. The tool is given the key messages document, the Phase 1 and 2 CTRs, and TFL shells with simulated data, so a full Phase 3 CTR, the clinical summaries and the clinical overview can be drafted before the results arrive. When headline results come in, the real data replace the simulated data, and writers focus on the sections where the outcome differs from what was expected. In Matilde’s words: “We don’t know yet how much time we’ll be able to save, but I think it looks very promising for us.”

Building AI capability across the team

Structured authoring is one of four pillars in Lundbeck’s AI strategy for medical writing, alongside complex regulatory documents, formatting and QC, and project management and personal productivity. The team built its skills step by step: access to tools, inspiration from external speakers, training on prompting frameworks and responsible use, then a test-and-try phase with shared learning, from one-to-one check-ins to an “AI tip of the month”.

Key takeaways

  • The CTR pilot gave Lundbeck reason to believe in GenAI structured authoring.
  • GenAI is not only about drafting faster: the opportunity is to shift the whole submission timeline forward.
  • The bottleneck is probably no longer technology, but capability building and behaviour change.

Watch the highlights above. To watch the full 13-minute session, complete the form and our team will email you access shortly.

Request the Full Recording

Watch the highlights, then request the full session.

By submitting this form, I accept to receive communications from AlphaLife Sciences in accordance with the Terms of our Privacy Policy

Thank You!

Thank you for your request. Our team will review it and email you access to the full recording shortly.

Close